SEC Company Response from Niki BioSolutions, (NIKI) — Dec 1, 2025
Niki BioSolutions, Inc.
Date: Dec. 1, 2025 · CIK: 0001734005 · Accession: 0001213900-25-116477
AI Filing Summary & Sentiment
File numbers found in text: 333-291593
Show Raw Text
CORRESP 1 filename1.htm APTORUM GROUP LIMITED 17 Hanover Square London W1S 1BN, United Kingdom December 1, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Science 100 F Street, N.E. Mail Stop 4631 Washington, DC 20549 Re: Aptorum Group Ltd Registration Statement on Form F-1 Filed November 17, 2025 File No. 333-291593 Dear Sir and Madam: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aptorum Group Limited hereby respectfully requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 2:00 p.m. Eastern Time on Wednesday, December 3, 2025, or as soon as thereafter practicable. The Company understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act as they relate to the offering of the securities specified in the Registration Statement. We thank the Staff for your review of the foregoing. If you have any further concerns, we ask that you forward them by electronic mail to our counsel, Louis Taubman at ltaubman@htflawyers.com or by telephone at (917) 512-0827. /s/ Ian Huen Ian Huen CEO cc: Louis Taubman Hunter Taubman Fischer& Li LLC